1. Home
  2. ALT vs HYI Comparison

ALT vs HYI Comparison

Compare ALT & HYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • HYI
  • Stock Information
  • Founded
  • ALT 1997
  • HYI 2010
  • Country
  • ALT United States
  • HYI United States
  • Employees
  • ALT N/A
  • HYI N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • HYI Investment Managers
  • Sector
  • ALT Health Care
  • HYI Finance
  • Exchange
  • ALT Nasdaq
  • HYI Nasdaq
  • Market Cap
  • ALT 333.6M
  • HYI 272.7M
  • IPO Year
  • ALT N/A
  • HYI N/A
  • Fundamental
  • Price
  • ALT $3.93
  • HYI $11.61
  • Analyst Decision
  • ALT Strong Buy
  • HYI
  • Analyst Count
  • ALT 6
  • HYI 0
  • Target Price
  • ALT $17.40
  • HYI N/A
  • AVG Volume (30 Days)
  • ALT 3.0M
  • HYI 50.6K
  • Earning Date
  • ALT 11-11-2025
  • HYI 01-01-0001
  • Dividend Yield
  • ALT N/A
  • HYI 9.59%
  • EPS Growth
  • ALT N/A
  • HYI N/A
  • EPS
  • ALT N/A
  • HYI N/A
  • Revenue
  • ALT $20,000.00
  • HYI N/A
  • Revenue This Year
  • ALT N/A
  • HYI N/A
  • Revenue Next Year
  • ALT N/A
  • HYI N/A
  • P/E Ratio
  • ALT N/A
  • HYI N/A
  • Revenue Growth
  • ALT N/A
  • HYI N/A
  • 52 Week Low
  • ALT $2.90
  • HYI $10.99
  • 52 Week High
  • ALT $11.16
  • HYI $12.24
  • Technical
  • Relative Strength Index (RSI)
  • ALT 52.80
  • HYI N/A
  • Support Level
  • ALT $3.85
  • HYI N/A
  • Resistance Level
  • ALT $4.06
  • HYI N/A
  • Average True Range (ATR)
  • ALT 0.20
  • HYI 0.00
  • MACD
  • ALT 0.02
  • HYI 0.00
  • Stochastic Oscillator
  • ALT 57.35
  • HYI 0.00

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About HYI Western Asset High Yield Defined Opportunity Fund Inc.

Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.

Share on Social Networks: